SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Morgan Stanley's 18th Annual Global Healthcare Conference at 3:45 p.m. ET on Monday, September 14, 2020.
A live webcast of the presentation and Q&A will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero Therapeutics
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial. Akero Therapeutics is headquartered in South San Francisco, CA. For more information, please visit www.akerotx.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-present-at-morgan-stanleys-18th-annual-global-healthcare-conference-301126806.html
SOURCE Akero Therapeutics, Inc.
Investor Contact: Christina Tartaglia, Stern Investor Relations, Inc., 212.362.1200, email@example.com, or Media Contact: Carolyn Hawley, Canale Communications, 619.849.5382, firstname.lastname@example.org